ReviewBlood and lymphatic cancer : targets and therapy2020

Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy.

Audrey M Sigmund et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.